Full TitleA Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive Stage Small Cell Lung Cancer (KEYNOTE B99)
The purpose of this study is to assess the safety and effectiveness of combining pembrolizumab immunotherapy with other anticancer medications as the first treatment for people with extensive-stage small cell lung cancer (ES-SCLC) that has spread or cannot be treated with radiation therapy. Pembrolizumab works by boosting the power of the immune system to find and kill cancer cells.
In this study, participants will be randomly assigned to receive pembrolizumab with either MK-4830, MK-5890, or lenvatinib. All participants will also receive the usual chemotherapy drugs approved to treat ES-SCLC (etoposide plus either cisplatin or carboplatin). All of these medications are given intravenously (by vein) except for lenvatinib, which is taken orally (by mouth).
To be eligible for this study, patients must meet several requirements, including:
- Participants must have ES-SCLC that has spread or cannot be treated with radiation therapy.
- Patients may not have received prior treatment for ES-SCLC.
- Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
- This study is for people age 18 and older.
For more information and to ask about eligibility for this study, please contact the office of Dr. Charles Rudin at 646-888-4527.